The active pharmaceutical ingredients (API) market is set to experience substantial growth in the coming years, fueled by technological advancements, the emergence of more efficient APIs with reduced side effects, and the increasing demand for affordable generic drugs. The API market offers substantial opportunities for pharmaceutical and biotechnology industries to develop dosage forms of new chemical entities, especially in high-end therapy areas like oncology and cardiovascular diseases.
The global API market was valued at $190.5 Billion in 2022 and is predicted to exceed $261.3 Billion by 2027, with a CAGR of 6.52 percent from 2022 to 2027. The API market is witnessing significant growth, primarily due to the increasing adoption of AI-based tools for drug discovery. AI plays a crucial role in target discovery, early drug development, and data analysis, leading to identifying new drug candidates and novel insights. This trend is expected to further propel the API market.
This edition of Pharma Tech Outlook brings to readers key developments in the active pharmaceutical ingredients space and how firms leverage the latest technology solutions to offer top-notch services. It features thought leadership articles from Sherene Min, VP, Head of Clinical Development at ViiV Healthcare, and Haichen Yang, MD, MA, MBA, Vice President, Clinical Research, Amicus Therapeutics Inc.
Sherene Min brings to attention the HIV epidemic, particularly children living with HIV. More children require access to HIV treatment as fewer antiretrovirals (ARVs) are available to the pediatric population. Better care can be delivered to children by raising awareness, developing appropriate drugs, garnering more support for pediatric clinical trials, and facilitating global partnerships. Haichen Yang talks about gene therapy’s challenges and clinical stages. Gene therapy shows promise for treating serious diseases without meaningful treatments, but it faces challenges. Transitioning preclinical gene therapy assets into clinical stages has proven challenging due to safety concerns, manufacturing difficulties, and complexities in clinical development.
This edition also features SK pharmteco, a company dedicated to advancing clinical development processes. Leveraging its extensive expertise in CDMO services for API development, SK pharmteco offers clients a competitive edge in manufacturing life-saving medications solutions.
In this edition featuring top active pharmaceutical ingredients solution providers, we hope you find the appropriate company suited to your business requirements.
